Journal Watch · Science Advances · 2026

<i>TP53</i>-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition.

These findings highlight a previously unappreciated <i>TP53</i>-altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.

Spinella JF, Chagraoui J, Moison C et al.Science Advances3 min readPharma relevance 50/100

DOI: 10.1126/sciadv.aed7122PMID: 42139355Study type: research study

TL;DR

These findings highlight a previously unappreciated <i>TP53</i>-altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.

Key findings

  • We show that this ribosomopathy-like phenotype is most pronounced in <i>TP53</i>-mutated cases with combined RPG deletions on chromosomes 3p and 5q, suggesting a cooperative oncogenic mechanism.
  • Chemical screening identified HSP90 inhibition as a selective vulnerability in AML with low RPG expression.
  • These findings highlight a previously unappreciated <i>TP53</i>-altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.

Numbers at a glance (from the abstract)

20%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Using the multidimensional Leucegene dataset (~700 primary AML specimens), we identified and comprehensively characterized a distinct subset of <i>TP53</i>-altered AML marked by recurrent deletions on the short arm of chromosome 3 [del(3p), >20% <i>TP53</i>-mutated cases]. These deletions frequently co-occur with del(5q) and encompass several ribosomal protein genes (RPGs), leading to a global down-regulation of the ribosomal network and reduced protein synthesis.

Full abstract (original)

Background: <i>TP53</i>-mutated acute myeloid leukemia (AML) represents a particularly aggressive and therapeutically refractory subtype of the disease. While recurrent chromosomal abnormalities such as -5/del(5q), -7/del(7q), and del(17p) are well studied in this context, additional co-occurring events remain less well defined.

What they did: Using the multidimensional Leucegene dataset (~700 primary AML specimens), we identified and comprehensively characterized a distinct subset of <i>TP53</i>-altered AML marked by recurrent deletions on the short arm of chromosome 3 [del(3p), >20% <i>TP53</i>-mutated cases]. These deletions frequently co-occur with del(5q) and encompass several ribosomal protein genes (RPGs), leading to a global down-regulation of the ribosomal network and reduced protein synthesis.

Results & conclusions: We show that this ribosomopathy-like phenotype is most pronounced in <i>TP53</i>-mutated cases with combined RPG deletions on chromosomes 3p and 5q, suggesting a cooperative oncogenic mechanism. Chemical screening identified HSP90 inhibition as a selective vulnerability in AML with low RPG expression. These findings highlight a previously unappreciated <i>TP53</i>-altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.

Abstract © the authors / Science Advances (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/sciadv.aed7122 · PubMed 42139355.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Science Advances for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Science Advances study find?

These findings highlight a previously unappreciated <i>TP53</i>-altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.

What type of study is this?

It is a research study, published in Science Advances in 2026. Using the multidimensional Leucegene dataset (~700 primary AML specimens), we identified and comprehensively characterized a distinct subset of <i>TP53</i>-altered AML marked by recurrent deletions on the short arm of chromosome 3 [del(3p), >20% <i>TP53</i>-mutated cases].

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/sciadv.aed7122. PubMed ID: 42139355. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Spinella JF, Chagraoui J, Moison C et al.. &lt;i&gt;TP53&lt;/i&gt;-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition.. Science Advances (2026). DOI: 10.1126/sciadv.aed7122.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/lt-i-gt-tp53-lt-i-gt-mutant-aml-with-ribosomal-gene-loss-exhibits-impair-ed7122/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides